ALLAKOS INC (ALLK)       7.21  -0.36 (-4.76%)

7.21  -0.36 (-4.76%)

US01671P1003 - Common Stock - After market: 7.2 -0.01 (-0.14%)

ALLAKOS INC7.21

NASDAQ:ALLK (2/3/2023, 7:24:30 PM)-0.36 (-4.76%)

After market: 7.2 -0.01 (-0.14%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-07 2022-11-07/amc Earnings (Next) 02-27 2023-02-27/amc
Ins Owners 3.47% Inst Owners 76.85%
Market Cap 614.32M Shares 85.20M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 54.12
IPO 07-19 2018-07-19

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALLK Daily chart

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in San Carlos, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Company Info

ALLAKOS INC

825 Industrial Road, Suite 500

San Carlos CALIFORNIA 94065

P: 16505975002.0

CEO: Robert Alexander

Employees: 192

Website: http://www.allakos.com/

ALLK News

News Image2 months ago - Allakos Inc.Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell inhibition in pre-clinical studies...

News Image2 months ago - Allakos Inc.Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications BiologyNews Image3 months ago - Allakos Inc.Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known...

News Image3 months ago - Allakos Inc.Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual MeetingNews Image3 months ago - Allakos Inc.Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...

News Image3 months ago - Allakos Inc.Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

ALLK Twits

Here you can normally see the latest stock twits on ALLK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example